Prasugrel Hydrochloride

製品コードS4637 バッチS463701

化学情報

	Synonyms	Prasugrel HCl, LY640315,PCR 4099 Hydrochloride	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₂₀H₂₀FNO₃S.HCl
	分子量	409.9	CAS No.	389574-19-0
Solubility (25°C)*	体外	DMSO	46 mg/mL (112.22 mM)
		Ethanol	9 mg/mL (21.95 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Prasugrel hydrochloride (Prasugrel HCl, LY640315,PCR 4099 Hydrochloride) is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.
in vivo	Prasugrel significantly inhibits arterio-venous (AV) shunt and electrically induced arterial thrombosis in single dose ranges of 0.3 to 3 mg/kg and of 0.3 and 1 mg/kg/day for multiple doses. These doses are similar to doses with inhibition of platelet activation via P2Y12 receptors, suggesting that the protective effects of prasugrel in these cerebral infarction and peripheral arterial occlusive disease models reflect P2Y12 inhibitions on platelets by prasugrel's active metabolite. Prasugrel also significantly prevents progression of peripheral vascular lesions^[1].

製品説明

Prasugrel hydrochloride (Prasugrel HCl, LY640315,PCR 4099 Hydrochloride) is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.

in vivo

Prasugrel significantly inhibits arterio-venous (AV) shunt and electrically induced arterial thrombosis in single dose ranges of 0.3 to 3 mg/kg and of 0.3 and 1 mg/kg/day for multiple doses. These doses are similar to doses with inhibition of platelet activation via P2Y12 receptors, suggesting that the protective effects of prasugrel in these cerebral infarction and peripheral arterial occlusive disease models reflect P2Y12 inhibitions on platelets by prasugrel's active metabolite. Prasugrel also significantly prevents progression of peripheral vascular lesions^[1].

プロトコル(参考用のみ)

動物実験	動物モデル	Sprague-Dawley rats; Wistar rats
	投薬量	0.03-10 mg/kg
	投与方法	p.o.

参考

[1] Ogawa T, et al. Eur J Pharmacol. 2009, 612(1-3):29-34.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Effect of RAD51C expression on the chemosensitivity of Eμ-Myc p19Arf-/- cells and its clinical significance in breast cancer [ Oncol Lett, 2018, 15(5):6107-6114]	PubMed: 29731842

Effect of RAD51C expression on the chemosensitivity of Eμ-Myc p19Arf-/- cells and its clinical significance in breast cancer [ Oncol Lett, 2018, 15(5):6107-6114]

PubMed: 29731842

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。